Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

3 Jul 2019

Abstract excerpt

Melanoma plasticity creates a plethora of opportunities for cancer cells to escape treatment. Thus, therapies must target all cancer cell subpopulations bearing the potential to contribute to disease. The role of the differentiation/pigmentation program in intrinsic and acquired drug resistance is largely uncharacterized. MITF level and expression of MITF-dependent pigmentation-related...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous Melanoma Detection and Management
Share to melanin and skin pigmentation
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31354817
DOI: 10.1155/2019/1697913

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation ProgramPMID 31354817Read ↗

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.Semantic proximity Read ↗

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.Semantic proximity Read ↗

Metabolic rewiring in melanoma drug-resistant cells.Semantic proximity Read ↗

The Slow Cycling Phenotype: A Growing Problem for Treatment Resistance in Melanoma.Semantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.Semantic proximity Read ↗

Quantitative landscapes reveal trajectories of cell-state transitions associated with drug resistance in melanomaSemantic proximity Read ↗

Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.Semantic proximity Read ↗

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR ExpressionSemantic proximity Read ↗

Redirecting resistance evolution in <i> BRAF <sup>V600</sup> </i> melanoma by inhibition of the peroxiredoxin-thioredoxin systemSemantic proximity Read ↗

Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblastsSemantic proximity Read ↗

Nongenetic Mechanisms of Drug Resistance in MelanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.